The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The phosphatidylinositol 3-kinase (PI3K) pathway is frequently dysregulated in ovarian cancer (OC).
• Previous trials of first-generation mammalian target of rapamycin (mTOR) inhibitors in OC yielded disappointing results, potentially due to lack of patient selection and resistance mechanisms.
• Novel agents targeting PI3K, Akt, and dual mTORC1/mTORC2 are under investigation.

Purpose of the Study:

• To review the relevance of the PI3K pathway in OC.
• To provide an update on clinical trials of novel PI3K inhibitors in OC.
• To address challenges including drug resistance and predictive biomarkers.

Main Methods:

• Review of preclinical data and clinical trials involving PI3K pathway inhibitors in OC.
• Analysis of specific histological subtypes and genetic alterations (PIK3CA, PTEN) relevant to PI3K pathway targeting.
• Discussion of combination strategies with chemotherapy, MEK inhibitors, anti-angiogenic therapy, and hormonal therapy.

Main Results:

• PI3K pathway inhibition may be most effective in selected OC subtypes (e.g., clear cell, endometrioid) with specific alterations (PIK3CA, PTEN).
• Combination therapies (chemotherapy, targeted agents) are likely necessary to overcome pathway redundancy and resistance.
• Development of predictive biomarkers is crucial for patient selection.

Conclusions:

• Targeting the PI3K/Akt/mTOR pathway holds potential in OC, but requires careful patient selection based on histology and molecular alterations.
• Novel inhibitors and rational combination strategies are essential for clinical success.
• Further research into predictive biomarkers and resistance mechanisms is critical for optimizing PI3K-targeted therapies in OC.